StudyID,Drug_Name,Arm_ID,Endpoint_Name,Endpoint_Type,Strategy,EP_P_value,Missing_Imput,Covariate_Adjust,MCP,Subgroup_Ana,EP_Value,EP_Unit,EP_Point,ARR,NNT,EP_95CI,Med_OS,OS_YrX,Med_PFS,ORR,pCR,Med_DOR,RMST,PRO,QoL,endpoint_group_id,endpoint_group_title_raw,endpoint_group_desc_raw,endpoint_group_title_norm,endpoint_group_desc_norm,matched_arm_id,arm_group_title_raw,arm_group_desc_raw,arm_group_title_norm,arm_group_desc_norm,match_type,title_score,desc_score,debug_notes,top_candidates_json
NCT01673867,,NCT01673867_P1,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint,Primary,,"[{""method"": ""Log Rank"", ""p"": {""value"": ""0.0015"", ""modifier"": """"}}]",,,,,"[{""measure_title"": ""Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""12.19"", ""lower"": ""9.66"", ""upper"": ""14.98""}]}]",Months,"[{""effect"": {""type"": ""Hazard Ratio (HR)"", ""value"": ""0.73""}}]",,,"[{""ci"": {""pct"": ""95.92"", ""lower"": ""0.59"", ""upper"": ""0.89""}}]",,,,,,,,,,O1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 61}, {""arm_id"": ""NCT01673867_A1"", ""arm_group_title_raw"": ""Arm A: Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 39}]"
NCT01673867,,NCT01673867_P2,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint,Primary,,"[{""method"": ""Log Rank"", ""p"": {""value"": ""0.0015"", ""modifier"": """"}}]",,,,,"[{""measure_title"": ""Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""9.36"", ""lower"": ""8.05"", ""upper"": ""10.68""}]}]",Months,"[{""effect"": {""type"": ""Hazard Ratio (HR)"", ""value"": ""0.73""}}]",,,"[{""ci"": {""pct"": ""95.92"", ""lower"": ""0.59"", ""upper"": ""0.89""}}]",,,,,,,,,,O2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 73}, {""arm_id"": ""NCT01673867_A2"", ""arm_group_title_raw"": ""Arm B: Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 33}]"
NCT01673867,,NCT01673867_P1,Objective Response Rate (ORR),Key Secondary,,[],,,,,"[{""measure_title"": ""Objective Response Rate (ORR)"", ""units"": ""Percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""19.5"", ""lower"": ""15.1"", ""upper"": ""24.5""}]}]",Percentage of participants,[],,,[],,,,,,,,,,O1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 61}, {""arm_id"": ""NCT01673867_A1"", ""arm_group_title_raw"": ""Arm A: Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 39}]"
NCT01673867,,NCT01673867_P2,Objective Response Rate (ORR),Key Secondary,,[],,,,,"[{""measure_title"": ""Objective Response Rate (ORR)"", ""units"": ""Percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""12.8"", ""lower"": ""9.1"", ""upper"": ""17.2""}]}]",Percentage of participants,[],,,[],,,,,,,,,,O2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 73}, {""arm_id"": ""NCT01673867_A2"", ""arm_group_title_raw"": ""Arm B: Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 33}]"
